CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics announced today that one of its proprietary Stapled Peptide compounds, referred to as “BIM-SAHB” in an article published today in Nature, was shown to uniquely target a new and fundamental activation mechanism of the programmed cell death or “apoptotic” pathway. Aileron has advanced an optimized version of the published Stapled Peptide compound into late-stage preclinical studies.
